Australia markets closed

PerkinElmer, Inc. (PKI)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
117.58-2.37 (-1.98%)
At close: 4:03PM EDT

117.28 -0.30 (-0.26%)
Before hours: 7:24AM EDT

PerkinElmer, Inc.

940 Winter Street
Waltham, MA 02451
United States
781 663 6900
http://www.perkinelmer.com

Sector(s)Healthcare
IndustryDiagnostics & Research
Full-time employees13,000

Key executives

NameTitlePayExercisedYear born
Dr. Prahlad R. Singh Ph.D.CEO, Pres & Director1.84M195.02k1965
Mr. James M. MockSr. VP & CFO901.44kN/A1977
Mr. Joel S. GoldbergSr. VP of Admin., Gen. Counsel & Sec.1.75M1.44M1969
Mr. Robert Francis FrielAdvisor6.9MN/A1956
Mr. Tajinder VohraSr. VP of Global OperationsN/AN/A1966
Amounts are as of 31 December 2019, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as laboratory services. It also provides analytical technologies, solutions, and services for the environmental, food, and industrial markets that enable its customers to understand the characterization and health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophym, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology and drug discovery. The company serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

Corporate governance

PerkinElmer, Inc.’s ISS governance QualityScore as of 9 December 2019 is 9. The pillar scores are Audit: 2; Board: 4; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.